Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cystic Fibrosis: Eurand Launches Zenpep, Joins Breed Of Remade Pancreatic Enzyme Products

This article was originally published in The Pink Sheet Daily

Executive Summary

Rival's claim that porcine-derived product trials took only treatment responders is "baloney," says Eurand lead investigator.

You may also be interested in...

This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT

Alnara claims its latest trial shows real-world effectiveness of liprotamase, formerly called Trizytek, and plans early 2010 NDA.

New Drug Approvals & Regulatory Updates, In Brief

Solvay's swine-based pancreatic enzyme product approved with REMS: On May 1 FDA granted Solvay Pharmaceuticals' Creon (pancrelipase) the first pancreatic enzyme insufficiency product approval under guidelines that bring the previously unregulated remedies under the FDA umbrella. At the same time the agency made clear its concerns for the class by requiring that CREON have a Risk Evaluation and Mitigation Strategy. As part of the classwide REMS, caregivers and patients are to receive a Medication Guide with dosing and safety information that emphasize the risk of fibrosing colonopathy, a rare adverse reaction in cystic fibrosis patients taking high doses of pancreatic enzyme replacement therapy, as well as the dangers of over- or under-dosing. It also notes the theoretical risk of cross-species infection with porcine viruses because Creon and similar products are derived from pig pancreases (1"The Pink Sheet," Dec. 8, 2008, p. 6). FDA-approved Creon will be available in the third quarter, but the 20-year-old currently marketed formulation will remain available until the launch, the company said

Pancreatic Insufficiency Drug Makers Given NDA Approval Deadline Of 2008

FDA is not removing unapproved products from the market because they are medically necessary. However, manufacturers must obtain approval of exocrine pancreatic insufficiency drugs within four years.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts